<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444028</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-101</org_study_id>
    <nct_id>NCT00444028</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine Single Dose PK</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of a Single Dose of Staccato™ Loxapine for Inhalation in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the safety, tolerability and pharmacokinetics of a
      single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and pharmacokinetic data obtained from 50 subjects (between the ages of 18 to 55
      years) entered into this randomized, placebo-controlled study. To obtain 50 enrolled
      subjects, screening procedures and inclusion/exclusion criteria were evaluated for 126
      subjects during a variable screening period of up to 21 days. Once enrolled, subjects were
      randomized to either Staccato Loxapine or Staccato placebo.

      Plasma samples for pharmacokinetic analysis were collected beginning on Day 0, pre-dose and
      continuing for 24 hr post dose. Blood samples for the PK analysis of loxapine and its
      metabolites (8-OH loxapine, 7-OH loxapine and amoxapine) were obtained at time 0 (immediately
      before dosing), at 30 sec, 1, 2, 3, 5, 10, 30, 45 min, 1, 2, 4, 6, 12, 24 hr after dosing.
      Plasma concentrations of loxapine and metabolites were used to estimate the following PK
      parameters for loxapine and its metabolites: area under the plasma concentration time curve
      from time 0 extrapolated to infinity (AUCinf), AUC from time 0 to time tlast, the last
      quantifiable concentration (AUClast), maximum observed plasma concentration (Cmax), observed
      time of Cmax (tmax), terminal phase elimination rate constant (ke), apparent terminal
      elimination half life calculated from ke (T½ ), apparent total body clearance / fraction
      absorbed calculated from AUCinf and dose (CL/F) (for loxapine and the metabolites where
      permitted by measurable concentrations).

      Safety was evaluated by the incidence of adverse events, clinical laboratory testing (blood
      chemistry, hematology, and urinalysis), physical examination, vital signs, pulse oximetry,
      postural vital signs, 12-lead electrocardiogram, pulmonary function tests, continuous 12-lead
      Holter monitoring, sedation assessments, akathisia assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>Tmax = time from inhalation to to maximum observed loxapine concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>Half-life of the terminal elimination phase of loxapine concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ke</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>clearance (CL/F) of lozxapine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>maximum concentration of loxapine observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Proportionality (AUCinf) by Power Analysis</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
    <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cohort A: Inhaled Loxapine 0.625 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Inhaled Loxapine 1.25 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Inhaled Loxapine 2.5 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: Inhaled Loxapine 5 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: Inhaled Loxapine 10 mg or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Loxapine 0.625 mg</intervention_name>
    <description>Single 0.625 mg (lowest) dose of inhaled loxapine</description>
    <arm_group_label>Cohort A: Inhaled Loxapine 0.625 mg or Placebo</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Loxapine 1.25 mg</intervention_name>
    <description>Single 1.25 mg (2nd) dose of inhaled loxapine</description>
    <arm_group_label>Cohort B: Inhaled Loxapine 1.25 mg or Placebo</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Loxapine 2.5 mg</intervention_name>
    <description>Single 2.5 mg (3rd) dose of inhaled loxapine</description>
    <arm_group_label>Cohort C: Inhaled Loxapine 2.5 mg or Placebo</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Loxapine 5 mg</intervention_name>
    <description>Single 5 mg (4th) dose of inhaled loxapine</description>
    <arm_group_label>Cohort D: Inhaled Loxapine 5 mg or Placebo</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Loxapine 10 mg</intervention_name>
    <description>Single 10 mg (5th) dose of inhaled loxapine</description>
    <arm_group_label>Cohort E: Inhaled Loxapine 10 mg or Placebo</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled Placebo (0 mg)</intervention_name>
    <description>Single placebo dose of inhaled loxapine</description>
    <arm_group_label>Cohort A: Inhaled Loxapine 0.625 mg or Placebo</arm_group_label>
    <arm_group_label>Cohort B: Inhaled Loxapine 1.25 mg or Placebo</arm_group_label>
    <arm_group_label>Cohort C: Inhaled Loxapine 2.5 mg or Placebo</arm_group_label>
    <arm_group_label>Cohort D: Inhaled Loxapine 5 mg or Placebo</arm_group_label>
    <arm_group_label>Cohort E: Inhaled Loxapine 10 mg or Placebo</arm_group_label>
    <other_name>PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between the ages of 18 to 55 years, inclusive.

          2. Subjects with a body mass index (BMI) ≥21 and ≤30.

          3. Subjects who speak, read, and understand English and are willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures.

          4. Subjects who are willing and able to be confined to the Clinical Research Unit (CRU)
             for approximately 2 days and comply with the study schedule and study requirements.

          5. Subjects who are in good general health as determined by a complete medical history,
             physical examination, 12-lead ECG, spirometry, blood chemistry profile, hematology,
             and urinalysis.

        Exclusion Criteria:

          1. Subjects who regularly consume large amounts of xanthine-containing substances (i.e.,
             more than 5 cups of coffee or equivalent amounts of xanthine-containing substances per
             day).

          2. Subjects who have taken prescription or nonprescription medication (with the exception
             of vitamins and acetaminophen if medically necessary) within 5 days of Visit 2
             (Baseline).

          3. Subjects who have had an acute illness within 5 days of Visit 2 (Baseline).

          4. Subjects who have received an investigational drug within 30 days (or within 5 half
             lives of the investigational drug, if &gt;30 days) prior to Visit 2 (Baseline).

          5. Subjects who have smoked tobacco within the last year.

          6. Subjects who have a history within the past 2 years of drug or alcohol dependence or
             abuse as defined by DSM-4.

          7. Subjects with a history of HIV positivity.

          8. Subjects with a history of allergy or intolerance to dibenzoxazepines (amoxapine and
             loxapine).

          9. Subjects with a known history of contraindications to anticholinergics (bowel
             obstructions, urinary retention, acute glaucoma).

         10. Subjects with a history of pheochromocytoma, seizure disorder, Parkinson's disease, or
             Restless Leg Syndrome (RLS).

         11. Subjects who test positive for alcohol or have a positive urine drug screen at Visit 1
             or Visit 2.

         12. Subjects who have hypotension (systolic blood pressure ≤90 mmHg, diastolic blood
             pressure ≤50 mmHg), or hypertension (systolic blood pressure ≥140 mmHg, diastolic
             blood pressure ≥90 mmHg).

         13. Subjects who have a clinically significant ECG abnormality.

         14. Subjects with a history of unstable angina, syncope, coronary artery disease,
             myocardial infarction, congestive heart failure (CHF), stroke, transient ischemic
             attack (TIA), or a neurological disorder.

         15. Subjects who have a history of pulmonary disease that precludes administration of
             Staccato Loxapine (asthma, bronchitis, bronchospasm, emphysema).

         16. Subjects who have an FEV1 less than 80% of predicted values on spirometry assessments
             at Visit 1.

         17. Female subjects who are breastfeeding or have a positive pregnancy test at Visit 1 or
             Visit 2.

         18. Female participants of child-bearing potential or within 1 year of menopause, and
             sexually active are excluded unless they use a medically acceptable and effective
             birth control method throughout the study and for 1 week following the end of the
             study. Medically acceptable methods of contraception include abstinence, diaphragm
             with spermicide, intrauterine device (IUD), condom with foam or spermicide, vaginal
             spermicidal suppository, surgical sterilization, and birth control pills. Unacceptable
             methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone.

         19. Subjects who have any other disease or condition, by history, physical examination, or
             laboratory abnormalities that in the investigator's opinion, would present undue risk
             to the subject, or may confound the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Stoltz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Pharmaceutical Services, GFI Research Center, Evansville, IN 47714</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc., d/b/a Covance GFI Research</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):169-79. doi: 10.1177/0091270009347866. Epub 2009 Nov 13.</citation>
    <PMID>19915181</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>November 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>November 17, 2018</last_update_submitted>
  <last_update_submitted_qc>November 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, Staccato Loxapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty subjects were recruited by and studied in the clinical researech unit (CRU). Study dates: 30 September 2005 through 22 November 2005</recruitment_details>
      <pre_assignment_details>To obtain 50 enrolled subjects, screening procedures and inclusion/exclusion criteria were evaluated for 126 subjects during a variable screening period of up to 21 days. No enrolled participants were excluded from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Staccato placebo inhalation device(s)</description>
        </group>
        <group group_id="P2">
          <title>Staccato Loxapine 0.625 mg</title>
          <description>inhalation of loxapine from a single 0.625 mg device</description>
        </group>
        <group group_id="P3">
          <title>Staccato Loxapine 1.25 mg</title>
          <description>inhalation of loxapine from a two 0.625 mg devices</description>
        </group>
        <group group_id="P4">
          <title>Staccato Loxapine 2.5 mg</title>
          <description>inhalation of loxapine from a single 2.5 mg device</description>
        </group>
        <group group_id="P5">
          <title>Staccato Loxapine 5 mg</title>
          <description>inhalation of loxapine from a single 5 mg device</description>
        </group>
        <group group_id="P6">
          <title>Staccato Loxapine 10 mg</title>
          <description>inhalation of loxapine from a two 5 mg devices</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Staccato placebo inhalation device(s)</description>
        </group>
        <group group_id="B2">
          <title>Staccato Loxapine 0.625 mg</title>
          <description>inhalation of loxapine from a single 0.625 mg device</description>
        </group>
        <group group_id="B3">
          <title>Staccato Loxapine 1.25 mg</title>
          <description>inhalation of loxapine from a two 0.625 mg devices</description>
        </group>
        <group group_id="B4">
          <title>Staccato Loxapine 2.5 mg</title>
          <description>inhalation of loxapine from a single 2.5 mg device</description>
        </group>
        <group group_id="B5">
          <title>Staccato Loxapine 5 mg</title>
          <description>inhalation of loxapine from a single 5 mg device</description>
        </group>
        <group group_id="B6">
          <title>Staccato Loxapine 10 mg</title>
          <description>inhalation of loxapine from a two 5 mg devices</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="10.55"/>
                    <measurement group_id="B2" value="33.4" spread="10.44"/>
                    <measurement group_id="B3" value="28" spread="7.11"/>
                    <measurement group_id="B4" value="28.2" spread="6.05"/>
                    <measurement group_id="B5" value="30.1" spread="13.53"/>
                    <measurement group_id="B6" value="27.4" spread="7.65"/>
                    <measurement group_id="B7" value="31.7" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Tmax = time from inhalation to to maximum observed loxapine concentration</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Tmax = time from inhalation to to maximum observed loxapine concentration</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="21.3"/>
                    <measurement group_id="O2" value="2.15" spread="1.31"/>
                    <measurement group_id="O3" value="2.87" spread="3.62"/>
                    <measurement group_id="O4" value="2.13" spread="0.687"/>
                    <measurement group_id="O5" value="5.25" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life</title>
        <description>Half-life of the terminal elimination phase of loxapine concentrations</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life</title>
          <description>Half-life of the terminal elimination phase of loxapine concentrations</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.3"/>
                    <measurement group_id="O2" value="6.56" spread="1.44"/>
                    <measurement group_id="O3" value="6.92" spread="1.94"/>
                    <measurement group_id="O4" value="6.2" spread="1.14"/>
                    <measurement group_id="O5" value="6.14" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ke</title>
        <description>elimination rate constant</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>ke</title>
          <description>elimination rate constant</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>/hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".143" spread=".047"/>
                    <measurement group_id="O2" value=".111" spread=".026"/>
                    <measurement group_id="O3" value=".108" spread=".033"/>
                    <measurement group_id="O4" value=".115" spread=".020"/>
                    <measurement group_id="O5" value=".122" spread=".032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance</title>
        <description>clearance (CL/F) of lozxapine</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <description>clearance (CL/F) of lozxapine</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="14.1"/>
                    <measurement group_id="O2" value="55.9" spread="13.7"/>
                    <measurement group_id="O3" value="61.1" spread="18.8"/>
                    <measurement group_id="O4" value="53.8" spread="9.74"/>
                    <measurement group_id="O5" value="78" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum concentration of loxapine observed</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum concentration of loxapine observed</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="8.79"/>
                    <measurement group_id="O2" value="9.7" spread="3.49"/>
                    <measurement group_id="O3" value="62.9" spread="63"/>
                    <measurement group_id="O4" value="105" spread="80.6"/>
                    <measurement group_id="O5" value="134" spread="118.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Proportionality (AUCinf) by Power Analysis</title>
        <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
        <time_frame>predose, 0.5, 1, 2, 3, 5, 10, 30 and 45 min, 1, 2, 4, 6, 12, and 24 hours</time_frame>
        <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Loxapine 0.625 mg</title>
            <description>inhalation of loxapine from a single 0.625 mg device</description>
          </group>
          <group group_id="O2">
            <title>Staccato Loxapine 1.25 mg</title>
            <description>inhalation of loxapine from a two 0.625 mg devices</description>
          </group>
          <group group_id="O3">
            <title>Staccato Loxapine 2.5 mg</title>
            <description>inhalation of loxapine from a single 2.5 mg device</description>
          </group>
          <group group_id="O4">
            <title>Staccato Loxapine 5 mg</title>
            <description>inhalation of loxapine from a single 5 mg device</description>
          </group>
          <group group_id="O5">
            <title>Staccato Loxapine 10 mg</title>
            <description>inhalation of loxapine from a two 5 mg devices</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Proportionality (AUCinf) by Power Analysis</title>
          <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
          <population>PK Population (N=36) All subjects exposed to inhaled loxapine who provided concentration data</population>
          <units>hr*mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="3.70"/>
                    <measurement group_id="O2" value="23.4" spread="4.87"/>
                    <measurement group_id="O3" value="44.6" spread="14.7"/>
                    <measurement group_id="O4" value="95.5" spread="16.6"/>
                    <measurement group_id="O5" value="140.6" spread="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>0.909</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.832</ci_lower_limit>
            <ci_upper_limit>0.987</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed at 17 pre-specified time points for the 24-hour period after dosing, as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Staccato placebo inhalation device(s)</description>
        </group>
        <group group_id="E2">
          <title>Staccato Loxapine 0.625 mg</title>
          <description>inhalation of loxapine from a single 0.625 mg device</description>
        </group>
        <group group_id="E3">
          <title>Staccato Loxapine 1.25 mg</title>
          <description>inhalation of loxapine from a two 0.625 mg devices</description>
        </group>
        <group group_id="E4">
          <title>Staccato Loxapine 2.5 mg</title>
          <description>inhalation of loxapine from a single 2.5 mg device</description>
        </group>
        <group group_id="E5">
          <title>Staccato Loxapine 5 mg</title>
          <description>inhalation of loxapine from a single 5 mg device</description>
        </group>
        <group group_id="E6">
          <title>Staccato Loxapine 10 mg</title>
          <description>inhalation of loxapine from a two 5 mg devices</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 8.0">Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Absolute bioavailability was not determined because loxapine for intravenous comparator was not available comercially in the US</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

